Minos mutagenesis

In the 15 November EMBO Reports Klinakis et al. describe a method for insertional mutagenesis and gene tagging that uses transposon-mediated mutagenesis (TRAMM) (EMBO Reports 2000, 1:416-421). They used two plasmid vectors, one encoding the Minos transposase enzyme from Drosophila hydrei and the other carrying a drug-resistance gene flanked by Minos inverted repeats. The naked DNA plasmids were transfected into human HeLa cells and about 4% of cells gave drug-resistant clones with multiple inser

By | November 28, 2000

In the 15 November EMBO Reports Klinakis et al. describe a method for insertional mutagenesis and gene tagging that uses transposon-mediated mutagenesis (TRAMM) (EMBO Reports 2000, 1:416-421). They used two plasmid vectors, one encoding the Minos transposase enzyme from Drosophila hydrei and the other carrying a drug-resistance gene flanked by Minos inverted repeats. The naked DNA plasmids were transfected into human HeLa cells and about 4% of cells gave drug-resistant clones with multiple insertions. Furthermore, a Minos-based gene trap system yielded about 80,000 insertions per million transfected cells. Insect transposons could therefore be used for high frequency insertion mutagenesis of the human genome in functional genomics and high-throughput screening. The TRAMM method is an improvement on existing insertion mutagenesis techniques; it overcomes the inefficiency of plasmid vector approaches and does not require the same level of experimental expertise needed for using retroviral vectors.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech